IONIQ Sciences / Awards and Recognition  / IONIQ is “Clinical Diagnostics Solution of the Year 2022”

IONIQ is “Clinical Diagnostics Solution of the Year 2022”

Salt Lake City, UT, December 19, 2022 – IONIQ Sciences, Inc. (“IONIQ” or the “Company”) is honored to be recognized as the “Clinical Diagnostics Solution of the Year 2022” by BioTech Breakthrough Awards (link). The IONIQ team is humbled by this award and recognition of our mission to modernize early-stage cancer detection. And we’re doing it with no needles, no radiation, and no surgery. In just 20 minutes. It won’t be long before annual wellness check-up’s include multi-cancer tests.

The world needs better early cancer detection. Two-thirds of all cancers are diagnosed in later stages when survival is dramatically lower due to shortcomings from today’s standard of care (imaging and liquid biopsies). The clinical evidence demonstrates that bioimpedance is an answer to these shortcomings.

At IONIQ, we’re using bioimpedance to look for something other technologies can’t see: the body’s oversized physiological response to the earliest stages of cancer. If we can catch cancer early, we’ll save lives. It’s that simple.

IONIQ can also reduce expensive shortcomings in today’s standard of care. 43% of diagnostic spend is on suspicious lung nodules that are ultimately benign. Understandably, physicians don’t want to miss cancer, and they lack tools to help them focus on true malignancies. Our technology can help identify benign nodules that don’t need to be biopsied. Because it’s not just about finding cancer – it’s about finding the truth.

About IONIQ Sciences, Inc.
IONIQ Sciences, Inc. is developing an advanced multi-cancer screening technology for early detection that has the potential to expand the therapeutic window, dramatically improve survivability and reduce the cost of healthcare. IONIQ Sciences operates at the confluence of its Electrical Impedance Analytics (EIA) or bioimpedance technology and Artificial Intelligence (AI). IONIQ Science’s first product utilizing its proprietary analytic platform, the IONIQ ProLung Test™ for lung cancer, has been designated a Breakthrough Device by the U.S. FDA.

About BioTech Breakthrough Awards
Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the BioTech Breakthrough Awards program is devoted to honoring excellence in life science and biotechnology solutions, services, and companies. The BioTech Breakthrough Awards provide public recognition for the achievements of biotechnology companies and products in categories including BioPharma, Genomics, Therapeutics, Food Science and BioAgriculture, and more. To learn more, please visit:

About BioHive

IONIQ Sciences is proud to be a key supporter and member of the newly formed BioHive, a collective representing the life science and healthcare innovation ecosystem. By embracing diversity and collaboration, BioHive has become the fastest-growing life science community in America and their innovations are improving the lives of millions of patients. To learn more, please visit:

For further information about IONIQ Sciences, Inc., please contact:
Andy Robertson | 1-801-736-0729 |
IONIQ Sciences, Vice President of Business Development

IONIQ Sciences, Inc.
350 W. 800 N., Suite 214
Salt Lake City, Utah 84103

Follow IONIQ Sciences, Inc. on Instagram, TwitterFacebook and LinkedIn: @IONIQSciences